89932-90-1Relevant academic research and scientific papers
Preparation method of ketoxime
-
Paragraph 0038-0040, (2018/07/30)
The invention belongs to the technical field of ketoxime and specifically relates to a preparation method of ketoxime. The preparation method comprises the following steps: (1) sufficiently mixing ketone and hydroxylamine hydrochloride, adding absolute ethyl alcohol, and stirring till total dissolution to obtain mixed liquid 1; (2) adding imidazolyl anion functionalized ionic liquid into the mixedliquid 1, and heating till ethanol reflux, wherein reaction liquid is obtained after the reaction; (3) removing ethanol in the reaction liquid, adding deionized water and stirring to separate out solid, and performing suction filtration and washing to obtain white solid ketoxime. According to the preparation method provided by the invention, by taking the imidazolyl anion functionalized ionic liquid as a catalyst, a reaction between ketone and hydroxylamine hydrochloride can be efficiently catalyzed, and the preparation method has the advantages of mild reaction conditions, high product yieldand purity and the like.
Novel bis(4-hydroxy) benzophenone oxime ether derivatives, preparation method thereof and composition for preventing or treating ER-related diseases comprising the same as an active ingredient
-
Paragraph 0098-0100, (2017/08/04)
The present invention relates to a novel bis(4-hydroxy) benzophenone oxime ether derivative, a preparation method thereof, and a composition for preventing or treating estrogen receptor-related diseases comprising the same as an active ingredient. The nov
Identification of novel estrogen receptor (ER) agonists that have additional and complementary anti-cancer activities via ER-independent mechanism
Kim, Taelim,Kim, Hye-In,An, Ji-Young,Lee, Jun,Lee, Na-Rae,Heo, Jinyuk,Kim, Ji-Eun,Yu, Jihyun,Lee, Yong Sup,Inn, Kyung-Soo,Kim, Nam-Jung
supporting information, p. 1844 - 1848 (2016/07/27)
In this study, a series of bis(4-hydroxy)benzophenone oxime ether derivatives such as 12c, 12e and 12h were identified as novel estrogen receptor (ER) agonists that have additional and complementary anti-proliferative activities via ER-independent mechanism in cancer cells. These compounds are expected to overcome the therapeutic limitation of existing ER agonists such as estradiol and tamoxifen, which have been known to induce the proliferation of cancer cells.
